USP expands role at upcoming PharmSci conference

The United States Pharmacopeia and AAPS are set to collaborate once more for the 2026 PharmSci 360 conference, which will take place in New Orleans from October 25 to 28. The event is scheduled to be hosted at the Ernest N. Morial Convention Center. This year marks a significant expansion of USP’s involvement compared to previous years, moving beyond standard exhibit-hall stage sessions into a dedicated two-and-a-half-day workshop format running from October 26 until the conclusion on the 28th.

The new workshop is located within the main exhibition hall and will focus on critical industry topics including complex generics, excipient quality standards, inhalation regulations, and novel excipients. The sessions are designed to address compendial standards found in the USP–NF publication. These specifications can be enforced by the FDA under the Federal Food, Drug, and Cosmetic Act. While specific speakers have not yet been announced for all segments of the event, USP staff members will hold various roles across the main scientific program, primarily acting as moderators rather than presenters.

Diane McCarthy, Ph.D., vice president of global biologics at USP, is scheduled to speak on Monday regarding future public standards for biologics development. Sheehan noted that the workshop aims to bring together diverse stakeholder perspectives to foster innovation and strengthen regulatory confidence. The agenda also covers a broad spectrum of topics across the pharmaceutical development pipeline, ranging from preclinical and clinical sciences through to translational research, formulation delivery, manufacturing processes, analytical characterization, and bioanalytics.

USP will maintain an exhibition presence at booth 2931 during the event and is presenting a special collection of posters. The collaboration underscores a shared mission between both organisations to assist industry partners and regulators in addressing evolving challenges within pharmaceutical quality. By integrating these perspectives, the organisers hope to ultimately increase the availability of high-quality medicines for patients who require them.

The conference programme continues to evolve as technology advances in data analysis and predictive analytics become central focuses for many professionals covering life sciences topics. Previous coverage has included extensive reporting on clinical trials, medical devices, drug discovery processes, and development strategies within the sector.